Symbols / AZTR $0.23 -1.49% Azitra, Inc.
AZTR Chart
About
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.74M |
| Enterprise Value | 2.15M | Income | -10.96M | Sales | — |
| Book/sh | 0.35 | Cash/sh | 0.13 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -0.44 | PEG | — |
| P/S | — | P/B | 0.65 | P/C | — |
| EV/EBITDA | -0.20 | EV/Sales | — | Quick Ratio | 2.07 |
| Current Ratio | 2.83 | Debt/Eq | 11.10 | LT Debt/Eq | — |
| EPS (ttm) | -2.25 | EPS next Y | -0.52 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-27 17:00 | ROA | -110.69% |
| ROE | -230.65% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 16.19M |
| Shs Float | 16.18M | Short Float | 2.16% | Short Ratio | 0.26 |
| Short Interest | — | 52W High | 2.67 | 52W Low | 0.10 |
| Beta | -2.17 | Avg Volume | 12.96M | Volume | 793.62K |
| Target Price | $1.35 | Recom | Buy | Prev Close | $0.23 |
| Price | $0.23 | Change | -1.49% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-24 | main | Maxim Group | Buy → Buy | $4 |
- AZTR Stock Price, Quote & Chart | AZITRA INC (NYSEARCA:AZTR) - ChartMill hu, 02 Apr 2026 07
- Azitra raises $10.5M to push wrinkle and skin-barrier biotech - Stock Titan hu, 19 Mar 2026 07
- Why Is AZTR Stock Rising Today? - Stocktwits Fri, 20 Mar 2026 14
- Azitra CEO-backed private placement priced up to $10.5M, potential $20.9M; stock jumps 90% (AZTR:NYSE) - Seeking Alpha Fri, 20 Mar 2026 07
- Why Is Azitra Inc Stock (AZTR) Up Today? - tipranks.com Fri, 20 Mar 2026 07
- Why Is Azitra (AZTR) Stock Soaring Today - Yahoo Finance Wed, 27 Aug 2025 07
- Azitra Inc. (AZTR) Surges Over 44% After Hours— Here's Why It's Trending - Benzinga Fri, 20 Mar 2026 07
- Azitra (AZTR) Stock Explodes 87% — Here’s What Triggered the Move - MEXC Fri, 20 Mar 2026 07
- Azitra Secures PIPE Financing to Advance Cosmetic Programs - The Globe and Mail ue, 24 Mar 2026 13
- AZTR SEC Filings - Azitra Inc 10-K, 10-Q, 8-K Forms - Stock Titan Fri, 20 Mar 2026 05
- Biotech Azitra warned on NYSE listing, auditor raises going-concern doubt - Stock Titan Fri, 13 Mar 2026 07
- Biotech Azitra backs rash and rare-skin trials, awaits 2026 data - Stock Titan Fri, 27 Feb 2026 08
- Azitra (NYSE: AZTR) secures up to $31.4M in PIPE with warrants - Stock Titan Mon, 23 Mar 2026 07
- Biotech Azitra scraps plans for March 6 special stockholder meeting - Stock Titan hu, 05 Mar 2026 08
- Shareholder vote stalls at Azitra with only 13% of stock voting - Stock Titan Fri, 06 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
-100.00%
|
0.01
-98.91%
|
0.69
+141.55%
|
0.28
|
| Operating Revenue |
|
0.00
-100.00%
|
0.01
-98.91%
|
0.69
+141.55%
|
0.28
|
| Operating Expense |
|
10.97
-0.24%
|
10.99
+35.10%
|
8.14
-16.44%
|
9.74
|
| Research And Development |
|
4.84
+2.38%
|
4.72
+29.65%
|
3.64
-40.25%
|
6.10
|
| Selling General And Administration |
|
6.13
-2.21%
|
6.27
+39.52%
|
4.49
+23.45%
|
3.64
|
| General And Administrative Expense |
|
6.13
-2.21%
|
6.27
+39.52%
|
4.49
+23.45%
|
3.64
|
| Other Gand A |
|
6.13
-2.21%
|
6.27
+39.52%
|
4.49
+23.45%
|
3.64
|
| Total Expenses |
|
10.97
-0.24%
|
10.99
+35.10%
|
8.14
-16.44%
|
9.74
|
| Operating Income |
|
-10.97
+0.17%
|
-10.99
-47.44%
|
-7.45
+21.19%
|
-9.45
|
| Total Operating Income As Reported |
|
-10.97
+0.17%
|
-10.99
-47.44%
|
-7.45
+21.19%
|
-9.45
|
| EBITDA |
|
-10.49
-23.40%
|
-8.50
+20.38%
|
-10.67
-6.49%
|
-10.02
|
| Normalized EBITDA |
|
-10.49
+16.32%
|
-12.53
-17.03%
|
-10.71
-6.84%
|
-10.02
|
| Reconciled Depreciation |
|
0.45
+1.09%
|
0.45
+5.33%
|
0.43
+4.82%
|
0.41
|
| EBIT |
|
-10.94
-22.28%
|
-8.95
+19.39%
|
-11.10
-6.43%
|
-10.43
|
| Total Unusual Items |
|
0.00
-99.99%
|
4.03
+11449.02%
|
0.03
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-99.99%
|
4.03
+11449.02%
|
0.03
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-10.96
-22.17%
|
-8.97
+20.53%
|
-11.28
-5.65%
|
-10.68
|
| Pretax Income |
|
-10.95
-22.20%
|
-8.96
+20.49%
|
-11.27
-5.49%
|
-10.68
|
| Net Non Operating Interest Income Expense |
|
0.06
-43.27%
|
0.11
+166.44%
|
-0.17
+32.75%
|
-0.25
|
| Interest Expense Non Operating |
|
0.01
-37.61%
|
0.01
-92.75%
|
0.17
-33.41%
|
0.25
|
| Net Interest Income |
|
0.06
-43.27%
|
0.11
+166.44%
|
-0.17
+32.75%
|
-0.25
|
| Interest Expense |
|
0.01
-37.61%
|
0.01
-92.75%
|
0.17
-33.41%
|
0.25
|
| Interest Income Non Operating |
|
0.07
-42.71%
|
0.12
+7671.27%
|
0.00
-67.27%
|
0.00
|
| Interest Income |
|
0.07
-42.71%
|
0.12
+7671.27%
|
0.00
-67.27%
|
0.00
|
| Other Income Expense |
|
-0.04
-102.24%
|
1.92
+152.50%
|
-3.65
-272.54%
|
-0.98
|
| Other Non Operating Income Expenses |
|
-0.04
+97.95%
|
-2.12
+42.52%
|
-3.68
-276.11%
|
-0.98
|
| Gain On Sale Of Security |
|
0.00
-99.99%
|
4.03
+11449.02%
|
0.03
|
—
|
| Tax Provision |
|
0.01
-7.88%
|
0.01
-47.82%
|
0.02
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
-99.99%
|
0.85
+11449.02%
|
0.01
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-10.96
-22.17%
|
-8.97
+20.53%
|
-11.28
-5.65%
|
-10.68
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.96
-22.17%
|
-8.97
+20.53%
|
-11.28
-5.65%
|
-10.68
|
| Net Income From Continuing And Discontinued Operation |
|
-10.96
-22.17%
|
-8.97
+20.53%
|
-11.28
-5.65%
|
-10.68
|
| Net Income Continuous Operations |
|
-10.96
-22.17%
|
-8.97
+20.53%
|
-11.28
-5.65%
|
-10.68
|
| Normalized Income |
|
-10.96
+9.86%
|
-12.15
-7.45%
|
-11.31
-5.91%
|
-10.68
|
| Net Income Common Stockholders |
|
-10.96
-22.17%
|
-8.97
+29.05%
|
-12.64
+6.02%
|
-13.45
|
| Diluted EPS |
|
—
|
-15.70
+95.71%
|
-366.17
-64.70%
|
-222.33
|
| Basic EPS |
|
—
|
-15.70
+95.71%
|
-366.17
-64.70%
|
-222.33
|
| Basic Average Shares |
|
—
|
0.57
+1554.87%
|
0.03
-42.95%
|
0.06
|
| Diluted Average Shares |
|
—
|
0.57
+1554.87%
|
0.03
-42.95%
|
0.06
|
| Diluted NI Availto Com Stockholders |
|
-10.96
-22.17%
|
-8.97
+29.05%
|
-12.64
+6.02%
|
-13.45
|
| Preferred Stock Dividends |
|
—
|
—
|
1.36
-51.05%
|
2.77
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
5.12
|
| Current Assets |
|
2.54
|
| Cash Cash Equivalents And Short Term Investments |
|
1.80
|
| Cash And Cash Equivalents |
|
1.80
|
| Receivables |
|
0.22
|
| Accounts Receivable |
|
0.10
|
| Taxes Receivable |
|
0.13
|
| Prepaid Assets |
|
0.45
|
| Current Deferred Assets |
|
0.07
|
| Total Non Current Assets |
|
2.58
|
| Net PPE |
|
1.58
|
| Gross PPE |
|
1.98
|
| Accumulated Depreciation |
|
-0.40
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
0.01
|
| Machinery Furniture Equipment |
|
0.06
|
| Other Properties |
|
1.88
|
| Leases |
|
0.03
|
| Goodwill And Other Intangible Assets |
|
0.21
|
| Other Intangible Assets |
|
0.21
|
| Non Current Deferred Assets |
|
0.74
|
| Other Non Current Assets |
|
0.05
|
| Total Liabilities Net Minority Interest |
|
2.20
|
| Current Liabilities |
|
1.60
|
| Payables And Accrued Expenses |
|
1.25
|
| Payables |
|
0.90
|
| Accounts Payable |
|
0.90
|
| Current Accrued Expenses |
|
0.35
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.03
|
| Total Tax Payable |
|
0.00
|
| Income Tax Payable |
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
0.32
|
| Current Capital Lease Obligation |
|
0.32
|
| Current Deferred Liabilities |
|
0.00
|
| Current Deferred Revenue |
|
0.00
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.60
|
| Long Term Debt And Capital Lease Obligation |
|
0.56
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
0.56
|
| Preferred Securities Outside Stock Equity |
|
0.00
|
| Stockholders Equity |
|
2.91
|
| Common Stock Equity |
|
2.91
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.06
|
| Ordinary Shares Number |
|
0.06
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
51.51
|
| Retained Earnings |
|
-48.60
|
| Total Equity Gross Minority Interest |
|
2.91
|
| Total Capitalization |
|
2.91
|
| Working Capital |
|
0.93
|
| Invested Capital |
|
2.91
|
| Total Debt |
|
0.89
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
0.89
|
| Net Tangible Assets |
|
2.70
|
| Tangible Book Value |
|
2.70
|
| Derivative Product Liabilities |
|
0.04
|
| Interest Payable |
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-11.22
-10.22%
|
-10.18
-38.32%
|
-7.36
+11.82%
|
-8.35
|
| Cash Flow From Continuing Operating Activities |
|
-11.22
-10.22%
|
-10.18
-38.32%
|
-7.36
+11.82%
|
-8.35
|
| Net Income From Continuing Operations |
|
-10.96
-22.17%
|
-8.97
+20.53%
|
-11.28
-5.65%
|
-10.68
|
| Depreciation Amortization Depletion |
|
0.45
+1.09%
|
0.45
+5.33%
|
0.43
+4.82%
|
0.41
|
| Depreciation |
|
0.44
+0.54%
|
0.44
+4.59%
|
0.42
+2.94%
|
0.41
|
| Amortization Cash Flow |
|
0.01
+22.83%
|
0.01
+46.06%
|
0.01
|
—
|
| Depreciation And Amortization |
|
0.45
+1.09%
|
0.45
+5.33%
|
0.43
+4.82%
|
0.41
|
| Amortization Of Intangibles |
|
0.01
+22.83%
|
0.01
+46.06%
|
0.01
|
—
|
| Other Non Cash Items |
|
0.01
-99.49%
|
2.13
-43.82%
|
3.80
+166.85%
|
1.42
|
| Stock Based Compensation |
|
0.06
-74.40%
|
0.25
+61.75%
|
0.15
-17.87%
|
0.18
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
0.44
+26.02%
|
0.35
|
0.00
|
| Operating Gains Losses |
|
0.00
+100.04%
|
-4.04
-8035.96%
|
-0.05
-799.77%
|
0.01
|
| Gain Loss On Investment Securities |
|
-0.00
+99.99%
|
-4.03
-11482.18%
|
-0.03
-4142.39%
|
-0.00
|
| Net Foreign Currency Exchange Gain Loss |
|
0.00
+100.00%
|
-0.01
|
0.00
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
-57.42%
|
0.00
-88.27%
|
0.04
+422.74%
|
0.01
|
| Change In Working Capital |
|
-0.80
-80.48%
|
-0.44
+41.37%
|
-0.75
-342.45%
|
0.31
|
| Change In Receivables |
|
-0.04
-134.34%
|
0.11
+168.50%
|
0.04
-35.90%
|
0.07
|
| Changes In Account Receivables |
|
-0.00
-100.69%
|
0.10
+15.91%
|
0.08
+485.21%
|
-0.02
|
| Change In Prepaid Assets |
|
0.05
+144.57%
|
-0.12
+58.59%
|
-0.29
-478.05%
|
-0.05
|
| Change In Payables And Accrued Expense |
|
-0.50
-256.01%
|
-0.14
-104.61%
|
-0.07
-116.32%
|
0.42
|
| Change In Payable |
|
—
|
-0.14
-104.61%
|
-0.07
-116.32%
|
0.42
|
| Change In Account Payable |
|
—
|
-0.14
-104.61%
|
-0.07
-116.32%
|
0.42
|
| Change In Other Working Capital |
|
-0.01
-128.88%
|
0.02
+111.80%
|
-0.16
-210.64%
|
0.14
|
| Change In Other Current Assets |
|
-0.00
-156.29%
|
0.00
+423.72%
|
-0.00
-136.46%
|
0.00
|
| Change In Other Current Liabilities |
|
-0.30
+3.46%
|
-0.32
-11.56%
|
-0.28
-5.43%
|
-0.27
|
| Investing Cash Flow |
|
-0.18
+51.77%
|
-0.38
-19.16%
|
-0.32
+5.49%
|
-0.34
|
| Cash Flow From Continuing Investing Activities |
|
-0.18
+51.77%
|
-0.38
-19.16%
|
-0.32
+5.49%
|
-0.34
|
| Net PPE Purchase And Sale |
|
-0.02
-145.77%
|
-0.01
+67.72%
|
-0.03
+8.00%
|
-0.03
|
| Purchase Of PPE |
|
-0.02
-182.57%
|
-0.01
+67.72%
|
-0.03
+19.81%
|
-0.03
|
| Sale Of PPE |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Capital Expenditure |
|
-0.19
+50.94%
|
-0.38
-19.16%
|
-0.32
+6.67%
|
-0.34
|
| Capital Expenditure Reported |
|
-0.16
+56.34%
|
-0.37
-27.07%
|
-0.29
+5.26%
|
-0.31
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
-0.13
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
-0.13
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
-0.18
|
| Financing Cash Flow |
|
8.92
-33.04%
|
13.32
+122.62%
|
5.98
+44.73%
|
4.13
|
| Cash Flow From Continuing Financing Activities |
|
8.92
-33.04%
|
13.32
+122.62%
|
5.98
+44.73%
|
4.13
|
| Net Issuance Payments Of Debt |
|
-0.02
-10.02%
|
-0.01
-97.48%
|
-0.01
-100.17%
|
4.35
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
4.35
|
| Repayment Of Debt |
|
-0.02
-10.02%
|
-0.01
-97.48%
|
-0.01
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
4.35
|
| Long Term Debt Payments |
|
-0.02
-10.02%
|
-0.01
-97.48%
|
-0.01
|
0.00
|
| Net Long Term Debt Issuance |
|
-0.02
-10.02%
|
-0.01
-97.48%
|
-0.01
-100.17%
|
4.35
|
| Net Common Stock Issuance |
|
9.03
-32.36%
|
13.35
+122.90%
|
5.99
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.02
|
0.00
-100.00%
|
0.00
|
| Net Other Financing Charges |
|
-0.10
-158.46%
|
-0.04
|
—
|
-0.22
|
| Changes In Cash |
|
-2.49
-190.14%
|
2.76
+262.60%
|
-1.70
+62.72%
|
-4.55
|
| Beginning Cash Position |
|
4.55
+153.61%
|
1.80
-48.58%
|
3.49
-56.58%
|
8.04
|
| End Cash Position |
|
2.07
-54.59%
|
4.55
+153.61%
|
1.80
-48.58%
|
3.49
|
| Free Cash Flow |
|
-11.41
-8.02%
|
-10.56
-37.53%
|
-7.68
+11.62%
|
-8.69
|
| Change In Income Tax Payable |
|
—
|
—
|
—
|
0.00
|
| Change In Tax Payable |
|
—
|
—
|
—
|
0.00
|
| Common Stock Issuance |
|
9.03
-32.36%
|
13.35
+122.90%
|
5.99
|
0.00
|
| Issuance Of Capital Stock |
|
9.03
-32.36%
|
13.35
+122.90%
|
5.99
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-23 View
- 42026-03-20 View
- 8-K2026-03-13 View
- 8-K2026-03-05 View
- 8-K2026-02-27 View
- 10-K2026-02-27 View
- 8-K2026-02-06 View
- 42025-12-22 View
- 42025-12-22 View
- 42025-12-22 View
- 42025-12-22 View
- 42025-12-22 View
- 8-K2025-12-17 View
- 8-K2025-11-25 View
- 8-K2025-11-12 View
- 10-Q2025-11-12 View
- 8-K2025-10-03 View
- 8-K2025-08-29 View
- 8-K2025-08-20 View
- 8-K2025-08-11 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|